The company has not filed an annual or quarterly report since its FY2020 10-K, filed Feb 25, 2021. Its latest SEC filing is a SC 13G/A from Feb 14, 2022.
10-K for FY2020, filed Feb 25, 2021
The sections below describe the company as of the FY2020 annual report.
Sells ePlex molecular diagnostic systems and test panels to hospitals, reference laboratories, and research institutions.
10-K for FY2020, filed Feb 25, 2021Our ePlex instrument is a multiplex, sample-to-answer platform that is designed to optimize laboratory efficiency and address a broad range…View ↗
We currently develop and commercialize high-value instruments and simple to perform, clinically relevant multiplex molecular panels based…View ↗
Our target customers include hospital-based and reference laboratories, as well as research institutions. We believe our ePlex system will…View ↗
Customers buy diagnostic tests and instruments, with product sales generally invoiced at shipment. Under reagent-rental agreements, customers commit to cartridge purchases and part of the cartridge charge covers instrument use; instrument services are billed as provided over the contract term.
10-K for FY2020, filed Feb 25, 2021Revenue from product sales is recognized generally upon shipment to the end customer, which is when control of the product is deemed to be…View ↗
Reagent Rental: A reagent rental agreement generally provides that a customer commits to purchase a minimum number of test cartridges over…View ↗
Revenue from operations includes revenue from the sale of our products and other services. Product revenue comprises the sale of diagnostic…View ↗
10-K for FY2020, filed Feb 25, 2021
FY2020 revenue by product or service (Product revenue) ↗$171.6M
10-K for FY2020, filed Feb 26, 2021
$171.6M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
ePlex Revenue
Sold outright
10-K for FY2020, filed Feb 25, 2021 |
90%
FY2017: 19%
|
ePlex Revenue, FY2020
$152.6M Sources
|
Sold outright |
|
XT-8 Revenue
Sold outright
10-K for FY2020, filed Feb 25, 2021 |
9.8%
FY2017: 81%
|
XT-8 Revenue, FY2020
$16.6M Sources
|
Sold outright |
Hospitals, reference laboratories, and research institutions are target buyers; U.S. products are sold through a direct sales and service team, while international ePlex sales primarily use distributors.
10-K for FY2020, filed Feb 25, 2021
10-K for FY2020, filed Feb 25, 2021
Our target customers include hospital-based and reference laboratories, as well as research institutions. We believe our ePlex system will…View ↗
No. It lost $18.6M in FY2020.
10-K for FY2020, filed Feb 26, 2021
−$11.1MView ↗
10-K for FY2020, filed Feb 26, 2021
−$18.6MView ↗
10-K for FY2020, filed Feb 26, 2021
−$11.6MView ↗
8-K, filed Apr 22, 2021
On April 22, 2021, pursuant to the terms of the Merger Agreement and in accordance with Section 251(h) of the Delaware General Corporation…View ↗
Grew. Revenue grew 3.5x in 4 years, from $49.3M in FY2016 to $171.6M in FY2020, about 37% a year.
New respiratory testing
The older report lists ePlex respiratory and bloodstream panels and a gastrointestinal panel under development; the later report adds a respiratory panel with another pathogen target and says sales of a separate test ended.
10-K for FY2017, filed Feb 25, 2019 10-K for FY2020, filed Feb 25, 2021In June 2017, we received 510(k) market clearance from the United States Food and Drug Administration (FDA) for both our ePlex instrument…View ↗
Competes with bioMerieux, Luminex, Danaher, Qiagen, Siemens, T2 BioSystems, Accelerate Diagnostics, Hologic, Seegene, Mobidiag, Qvella, Curetis, Bosch/Randox, aprimeo diagnostics, Roche Diagnostics, and Abbott Molecular Diagnostics
10-K for FY2020, filed Feb 25, 2021We primarily face competition in the molecular diagnostic testing markets with testing products and systems developed by public and private…View ↗
Loading...
